why wouldn't they as long as safety checks out.
I think you guys are looking way too much into the percentages of a very small trial. 11 people and only 6 showed disease control. That will skew the percentages. Wait for 50-60 patient trial
Rose colored glasses aside, the market didn't re-rate on the back of the 1a data, likely because it's way too small and didn't show anything conclusive. More of the same old same old as all other trials. 3 years down and many more years to go.
IPO at 20c, now at 2.5c. Management pay themselves as if they are running a fortune 500 company. That is never a good sign. Taking as much as they can before this goes to zero
why wouldn't they as long as safety checks out. I think you guys...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $49.02K | 2.700M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 540219 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 300790 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.8¢ |
Change
0.000 ( 4.76 %) |
||||
| Open | High | Low | Volume | ||
| 1.9¢ | 1.9¢ | 1.7¢ | 1522243 | ||
| Last updated 15.13pm 31/05/2024 ? | |||||
| CHM (ASX) Chart |